Hypocalcemia in cancer of the prostate: existence of an antivitamin D factor?
Arlet, P.; Blasco, A.; Duffaut, M.; Botreau, Y.; Le Tallec, Y.
La Nouvelle Presse Medicale 9(24): 1714-1715
1980
ISSN/ISBN: 0301-1518 PMID: 7465407 Document Number: 158716
Document emailed within 1 workday
Related Documents
Roach, M. 1998: Is race an independent prognostic factor for survival from prostate cancer? Journal of the National Medical Association 90(11 Suppl): S713-S719Zhong, H.; Agani, F.; Baccala, A.A.; Laughner, E.; Rioseco-Camacho, N.; Isaacs, W.B.; Simons, J.W.; Semenza, G.L. 1998: Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer Cancer Research 58(23): 5280-5284
Saitou, Y.; Hatanaka, Y.; Imanishi, M.; Ohzeki, T.; Hashimoto, K.; Sugimoto, K.; Esa, A.; Kajikawa, H.; Yasuda, M.; Yamamoto, Y.; Uemura, H. 2012: Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel Hinyokika Kiyo. Acta Urologica Japonica 58(1): 7-11
Hull, B.L.; Wass, W.M. 1973: Abomasal displacement. 2. Hypocalcemia as a contributing causative factor Veterinary Medicine-Small Animal Clinician 68(4): 412 Passim
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Huynh, H.; Nguyen, T.Thanh.Tuyen.; Chan, E.; Tran, E. 2003: Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation International Journal of Oncology 23(3): 821-829
Ismail, A.H.; Altaweel, W.; Chevalier, S.; Kassouf, W.; Aprikian, A.G. 2004: Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer Canadian Journal of Urology 11(1): 2146-2150
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Levine, L.; Lucci, J.A.; Pazdrak, B.; Cheng, J.-Z.; Guo, Y.-S.; Townsend, C.M.; Hellmich, M.R. 2003: Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells Cancer Research 63(13): 3495-3502
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Massey, C.D.; Wang, C.; Donovan, G.A.; Beede, D.K. 1993: Hypocalcemia at parturition as a risk factor for left displacement of the abomasum in dairy cows Journal of the American Veterinary Medical Association 203(6): 852-853
Olapade-Olaopa, E.O.; Moscatello, D.K.; MacKay, E.H.; Sandhu, D.P.S.; Terry, T.R.; Wong, A.J.; Habib, F.K. 2004: Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer African Journal of Medicine and Medical Sciences 33(3): 245-253
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Yang, J.; Zhang, J.-y.; Wang, Y.-m.; Shao, P.-f.; Song, N.-h.; Hua, L.-x.; Zhang, W. 2015: Expression ratio of the nerve growth factor receptor TrkA to p75NTR correlates with the clinical stage and pathological grade of prostate cancer Zhonghua Nan Ke Xue 21(11): 982-987